Daiichi Sankyo and Ranbaxy extend hybrid business model to Venezuela
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo and its Indian arm, Ranbaxy Laboratories, are continuing to pursue their hybrid business model, this time in Venezuela, the third-largest pharmaceutical market in Latin America.